Development of Carrier Free Montelukast Dry Powder Inhalation Formulation

Rubrik: Originale

(Treffer aus pharmind, Nr. 10, Seite 1535 (2015))

Faramarzi P | Haririan I | Ghanbarzadeh S | Yaqoubi S | Hamishehkar H

Development of Carrier Free Montelukast Dry Powder Inhalation Formulation / Faramarzi et al. • Montelukast Dry Powder Inhalation · Faramarzi P, Haririan I, Ghanbarzadeh S, Yaqoubi S, Hamishehkar H · ¹Department of Pharmaceutics, School of Pharmacy, International Campus, Tehran University of Medical Sciences (IC-TUMS), Tehran, Iran und ²Biomaterials Research Center (BRC), Tehran University of Medical Sciences (IC-TUMS), Tehran, Iran und ³Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran und ⁴Department of Pharmaceutics, Faculty of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran und ⁵Biotechnology Research Center and Students’ Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran und ⁶Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Montelukast sodium Dry powder inhaler Spray drying technique Pulmonary drug delivery DPI Asthma is a hypersensitivity disorder of the airways, characterized by chronic inflamed and easily collapsible airways as well as reversible airway obstruction [ 1 ]. Numerous approaches can serve as treatments for this disease, particularly the pulmonary drug delivery route, which represents an appealing and encouraging way to localize treatment of respiratory diseases like asthma [ 2 ]. The main advantages of the pulmonary route compared with other drug administration routes are associated with the large alveolar surface area suitable for drug absorption and extensive vascularization with the relatively low ...